---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-080529"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2022-03-21T23:59:59+00:00"
generated_at: "2026-06-26T21:28:01.393000+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ORIC discontinues ORIC-101 after Phase 1b failures; cash runway extended to 2H 2024

## Summary
- ORIC-101 discontinued after interim Phase 1b analyses showed insufficient activity; median PFS 3.7 months in prostate, 1.9 months in pancreatic cohorts.
- Focus shifts to three single-agent Phase 1b programs: ORIC-533 (multiple myeloma), ORIC-114 (EGFR/HER2), ORIC-944 (prostate); initial data expected 1H 2023.
- Cash and investments $280.4M as of Dec 31, 2021; cash runway extended into second half of 2024 following ORIC-101 discontinuation.
- Q4 2021 R&D expenses $16.7M (vs $12.1M Q4 2020); G&A $6.1M (vs $4.3M); increases driven by program advancement and public company costs.

## SEC filing metadata
- accession: 0001193125-22-080529
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2022-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312522080529/0001193125-22-080529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312522080529/d323230d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-080529
- JSON: https://secwatch.observer/filing/0001193125-22-080529.json
- Plain text: https://secwatch.observer/filing/0001193125-22-080529.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.